Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TroVax: Phase III ongoing

OXB enrolled 350 of a planned 700 patients in the double-blind,

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE